GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Ending Cash Position

Nanomix (Nanomix) Ending Cash Position : $0.02 Mil (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Nanomix Ending Cash Position?

Nanomix's Ending Cash Position for the quarter that ended in Dec. 2022 was $0.02 Mil.

Nanomix's quarterly Ending Cash Position increased from Jun. 2022 ($0.01 Mil) to Sep. 2022 ($0.05 Mil) but then declined from Sep. 2022 ($0.05 Mil) to Dec. 2022 ($0.02 Mil).

Nanomix's annual Ending Cash Position increased from Dec. 2020 ($0.02 Mil) to Dec. 2021 ($0.30 Mil) but then declined from Dec. 2021 ($0.30 Mil) to Dec. 2022 ($0.02 Mil).

Nanomix Ending Cash Position Historical Data

The historical data trend for Nanomix's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanomix Ending Cash Position Chart

Nanomix Annual Data
Trend Dec20 Dec21 Dec22
Ending Cash Position
0.02 0.30 0.02

Nanomix Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.30 0.01 0.01 0.05 0.02

Nanomix Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Nanomix's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.297+-0.28
=0.02

Nanomix's Ending Cash Position for the quarter that ended in Dec. 2022 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.05+-0.033
=0.02

Nanomix Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Nanomix's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanomix (Nanomix) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Ending Cash Position
Comparable Companies
VRAYQ ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA XSWX:SOON ALGN SHSE:688271 ASX:COH LSE:SN. PODD OCSE:DEMANT BRKR BIO
Traded in Other Exchanges
N/A
Address
2121 Williams Street, San Leandro, CA, USA, 94577
Website
https://www.nanomixdx.com
Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.
Executives
Chris Hetterly officer: Chief Financial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener director, 10 percent owner ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger director, officer: CEO C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney officer: Chief Operating Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky officer: Chief Commercial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson director, officer: CEO and President BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman director 1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham officer: Chief Operating Officer C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch director, officer: CEO
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng director ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia officer: Chief Financial Officer PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin director C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome officer: Chief Operating Officer (3) 178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz director 33 KACHAL STREET, LEHAVIM L3 85338